Literature DB >> 10023001

Expression of Thomsen-Friedenreich antigen as a marker of poor prognosis in pulmonary adenocarcinoma.

I Takanami1.   

Abstract

The prognostic significance of Thomsen-Frienden-reich antigen (T antigen) expression was investigated in 126 patients with pulmonary adenocarcinoma by immunohistochemical staining of tumor specimens with a monoclonal antibody specific for T antigen. T antigen immunoreactivity was detected in tumor tissue from 60 (48%) patients. T antigen expression did not correlate with gender, tumor size, presence of lymph node or distant metastasis, stage of disease, or degree of tumor cell differentiation. However, the presence of T antigen immunoreactivity correlated significantly with overall survival. The presence of T antigen immunoreactivity in tumor cells is a useful marker of prognosis in patients with pulmonary adenocarcinoma.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10023001     DOI： 10.3892/or.6.2.341

Source DB:  PubMed          Journal:  Oncol Rep        ISSN： 1021-335X            Impact factor:   3.906


  11 in total

1.  Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells.

Authors:  Wei-Ming Lin; Uwe Karsten; Steffen Goletz; Ruo-Chuan Cheng; Yi Cao
Journal:  Int J Exp Pathol       Date:  2010-11-11       Impact factor: 1.925

2.  Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen.

Authors:  Richa Chaturvedi; Jamie Heimburg; Jun Yan; Stephen Koury; Munawwar Sajjad; Hani H Abdel-Nabi; Kate Rittenhouse-Olson
Journal:  Appl Radiat Isot       Date:  2007-08-17       Impact factor: 1.513

3.  CHoMP: a chemoenzymatic histology method using clickable probes.

Authors:  Sara H Rouhanifard; Aimé López-Aguilar; Peng Wu
Journal:  Chembiochem       Date:  2014-11-17       Impact factor: 3.164

4.  Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.

Authors:  Christian Schindlbeck; Udo Jeschke; Sandra Schulze; Uwe Karsten; Wolfgang Janni; Brigitte Rack; Harald Sommer; Klaus Friese
Journal:  Histochem Cell Biol       Date:  2005-05-12       Impact factor: 4.304

Review 5.  Cancer vaccines and carbohydrate epitopes.

Authors:  Jamie Heimburg-Molinaro; Michelle Lum; Geraldine Vijay; Miten Jain; Adel Almogren; Kate Rittenhouse-Olson
Journal:  Vaccine       Date:  2011-10-01       Impact factor: 3.641

6.  Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11.

Authors:  Jamie Heimburg; Jun Yan; Susan Morey; Olga V Glinskii; Virginia H Huxley; Linda Wild; Robert Klick; Rene Roy; Vladislav V Glinsky; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

7.  p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer.

Authors:  Sabine Heublein; Sabina K Page; Doris Mayr; Nina Ditsch; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-02       Impact factor: 4.553

8.  Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.

Authors:  Christian Schindlbeck; Julia Stellwagen; Udo Jeschke; Uwe Karsten; Brigitte Rack; Wolfgang Janni; Julia Jückstock; Augustinos Tulusan; Harald Sommer; Klaus Friese
Journal:  Clin Exp Metastasis       Date:  2008-01-10       Impact factor: 5.150

Review 9.  Interaction of the Oncofetal Thomsen-Friedenreich Antigen with Galectins in Cancer Progression and Metastasis.

Authors:  Paulina Sindrewicz; Lu-Yun Lian; Lu-Gang Yu
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244

10.  Binding of galectin-1 to breast cancer cells MCF7 induces apoptosis and inhibition of proliferation in vitro in a 2D- and 3D- cell culture model.

Authors:  Pamina Geiger; Barbara Mayer; Irmi Wiest; Sandra Schulze; Udo Jeschke; Tobias Weissenbacher
Journal:  BMC Cancer       Date:  2016-11-08       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.